Is Veracyte (VCYT) Undervalued On New Genomics Data And Prosigna Coverage?

Veracyte (VCYT) just put fresh data and reimbursement clarity in front of oncologists and payors. New cancer genomics studies at ESMO 2026 and MolDX coverage for its Prosigna test are now in focus.

Recent headlines have arrived against a choppy backdrop for Veracyte’s stock, with a 10.06% 1 month share price return partly offsetting a 24.50% decline over the past 90 days. At the same time, a 21.33% 1 year total shareholder return and 104.10% 3 year total shareholder return point to momentum that has been building over a longer horizon as investors reassess growth potential and risks around the company’s cancer genomics portfolio.

Compare Veracyte’s genomics momentum with other potential cancer diagnostics opportunities by scanning a curated list of 33 healthcare AI stocks aligned with data driven medicine and reimbursement tailwinds.

The recent rebound in Veracyte after a sharp 90 day slide now meets a price sitting about one third below the average analyst target. Is that discount justified, or does fair value land closer to the estimates range?

Most Popular Narrative: 23% Undervalued

Veracyte’s most followed narrative pegs fair value at $56.55, compared with a last close of $43.80. This implies a sizeable valuation gap that investors now need to test against the underlying cancer diagnostics thesis.

Pipeline momentum, with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months, positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (e.g., MRD in bladder cancer, Prosigna for breast cancer), and significantly expand addressable markets, supporting long-term topline acceleration.

See why 13 investors see Veracyte as 23% undervalued.

Result: Fair Value of $56.55 (UNDERVALUED)

Still, Veracyte’s heavy reliance on Afirma and Decipher, together with ongoing reimbursement and regulatory pressure on genomic testing, could quickly challenge the current undervaluation story.

Find out about the key risks to this Veracyte narrative.

Next Steps

Mixed signals around Veracyte can be useful if you move fast and test them yourself against the data and risks. To see both sides of the debate in one place, review the 4 key rewards and 1 important warning sign.

Looking for more Veracyte style investment ideas?

If you stop with Veracyte, you only see one angle. Broaden the opportunity set now and pressure test your thesis against other high quality setups using the Simply Wall Street Screener.

• Target steady compounding potential by reviewing businesses built to defend and sustain income streams through the 8 dividend fortresses.
• Hunt for quality at a discount by comparing valuations and balance sheet strength inside the 35 high quality undervalued stocks.
• Prioritise resilience first by checking companies that pair financial stability with disciplined fundamentals in the list of solid balance sheet and fundamentals (25 results).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com